Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterCorrespondence

Race and Methotrexate Pharmacogenetics in Rheumatoid Arthritis

PRABHA RANGANATHAN and HOWARD McLEOD
The Journal of Rheumatology May 2010, 37 (5) 1064; DOI: https://doi.org/10.3899/jrheum.091095
PRABHA RANGANATHAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: prangana@dom.wustl.edu
HOWARD McLEOD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

Fisher and Cronstein are to be commended for their recent metaanalysis on methylenetetrahydrofolate reductase (MTHFR) polymorphisms and methotrexate (MTX) toxicity in rheumatoid arthritis (RA)1. Their work exposes the lack of sound pharmacogenetic data on MTX in RA and underscores that there is a long way to go before MTX pharmacogenetics is ready to guide clinical decision-making in RA.

In the discussion, the authors note the paucity of data in the literature to determine whether the presence or absence of a single-nucleotide polymorphism (SNP) has an effect on time to adverse events from MTX. We have reported that the presence of ABCC2 IVS 23+56 T>C, an intronic SNP in one of the ABC transporter genes, correlated with time to MTX discontinuation and/or dose decrease due to toxicity in Caucasian patients with RA (p < 0.0001)2. Although this is not a MTHFR SNP, to our knowledge, this is the only study to date to demonstrate such a genotype to time to MTX discontinuation association.

The authors also point out that none of the studies included in the analysis provided details on the racial background of the participants and emphasize the importance of race in influencing pharmacogenetics in different populations. Indeed, the SNP frequencies in several of the key genes in MTX pharmacogenetics including MTHFR differ significantly by race3,4. Further, we have shown that genotype-toxicity associations vary by race. In our cohort of Caucasians and African Americans with RA, we found that the MTHFR 677 C>T SNP was associated with MTX toxicity in African Americans with RA but not in Caucasians, and the intronic ABCC2 SNP with time to MTX discontinuation in Caucasians as described above, but not in African Americans with RA2. Others have demonstrated the MTHFR 677 C>T SNP to be associated with MTX toxicity in Caucasians and African Americans with RA4. These results supplement those of Fisher and Cronstein’s metaanalysis, which showed the MTHFR 677 C>T SNP to be associated with MTX toxicity in studies that examined populations of Caucasians and Asians, but did not include African Americans. We concede that the sample sizes of these studies were small, a problem all too common with almost all the studies related to MTX pharmacogenetics in RA.

Fisher and Cronstein’s metaanalysis once again demonstrates the futility of small-scale pharmacogenetic studies in providing meaningful results that can be applied to individualize patient therapy in clinical practice. Collaborative, multicenter, adequately powered studies, stratified by race, are needed to clarify the muddled state that exists in MTX pharmacogenetics today.

REFERENCES

  1. 1.↵
    1. Fisher MC,
    2. Cronstein BN
    . Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 2009;36:539–45.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Ranganathan P,
    2. Culverhouse R,
    3. Marsh S,
    4. Mody A,
    5. Scott-Horton TJ,
    6. Brasington R,
    7. et al.
    Methotrexate pathway gene polymorphisms and their effects on methotrexate toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 2008;35:572–9.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Ranganathan P,
    2. Culverhouse R,
    3. Marsh S,
    4. Ahluwalia R,
    5. Shannon WD,
    6. Eisen S,
    7. et al.
    Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis. Pharmacogenomics 2004;5:559–69.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Hughes LB,
    2. Beasley TM,
    3. Patel H,
    4. Tiwari HK,
    5. Morgan SL,
    6. Baggott JE,
    7. et al.
    Racial or ethnic differences in allele frequencies of single nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis 2006;65:1213–8.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 37, Issue 5
1 May 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Race and Methotrexate Pharmacogenetics in Rheumatoid Arthritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Race and Methotrexate Pharmacogenetics in Rheumatoid Arthritis
PRABHA RANGANATHAN, HOWARD McLEOD
The Journal of Rheumatology May 2010, 37 (5) 1064; DOI: 10.3899/jrheum.091095

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Race and Methotrexate Pharmacogenetics in Rheumatoid Arthritis
PRABHA RANGANATHAN, HOWARD McLEOD
The Journal of Rheumatology May 2010, 37 (5) 1064; DOI: 10.3899/jrheum.091095
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Dr. Putman et al reply
  • Drs. Chung and McMahan reply
  • Dr. Deng et al reply
Show more Correspondence

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire